AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
How to mod spore 20194/4/2024 ![]() The long-term follow-up of patients with metastatic RCC treated with these novel immune approaches will be awaited to assess their curative potential. Therapeutic strategies using immune checkpoint antibodies are revolutionizing the treatment of many cancers including RCC, but at best 50% of patients with metastatic RCC respond to the combination of anti-PD-1 and anti-CTLA-4 antibodies. Currently, there is no established effective therapy for this diverse group of non-clear cell RCC subtypes. Furthermore, insight into the biology of non-clear cell RCC subtypes has lagged behind clear-cell RCC, with few relevant targets identified. Despite the clinical efficacy of targeted agents, significant toxicity hampers patient benefit, and five years. However, the vast majority of patients develop progressive disease within a year. There has been significant progress made in the treatment of clear-cell renal cell carcinoma (RCC), with several targeted agents now approved. ![]()
0 Comments
Read More
Leave a Reply. |